Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study-Reference-Cited by-同舟云学术

Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study

Published:2019-07-01 Issue:5 Volume:86 Page:628-634
ISSN:0031-3998
Container-title:Pediatric Research
language:en
Short-container-title:Pediatr Res

Author:

Lin Yuh-Jyh,Chung Ching-Hu,Chi Hsin,Lin Chyi-Her

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology and Child Health

Link

http://www.nature.com/articles/s41390-019-0492-7.pdf

Reference33 articles.

1. Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946–958 (2017).

2. Polack, F. P. The changing landscape of respiratory syncytial virus. Vaccine 33, 6473–6478 (2015).

3. Krilov, L. R. et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 14, 261 (2014).

4. Pediatrics, A. A. P. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102, 1211–1216 (1998).

5. American Academy of Pediatrics Committee on Infectious D, Committee on F, Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112, 1442–1446 (2003).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic characterization of respiratory syncytial virus surface glycoproteins F and G in Taiwan, 2017–2021;Journal of Microbiology, Immunology and Infection;2024-08

2. Risk Factors for Severe Respiratory Syncytial Virus Infection in Hospitalized Children;Pediatric Infectious Disease Journal;2024-01-31

3. Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia;Journal of Allergy and Clinical Immunology: Global;2023-11

4. Oxidative stress and ROS-mediated cellular events in RSV infection: potential protective roles of antioxidants;Virology Journal;2023-10-05

5. Desenlaces clínicos generados por la infección del virus sincitial respiratorio durante los primeros dos años de vida en pacientes de un programa canguro que recibieron profilaxis completa con palivizumab. Estudio de cohorte retrospectivo;Pediatría;2023-03-31